AstraZeneca has partnered with the Philippine Economic Zone Authority to establish the country's first pharmaceutical innovation hub, focusing on cancer care, digital health, and research collaboration, solidifying the Philippines' position as Southeast Asia's largest pharma market.

Sumitomo Pharma detailed its R&D strategy on February 17, 2026, highlighting enzomenib confirmatory trials, nuvisertib Phase 1/2 advancements, and raguneprocel submission for Parkinson's under Sakigake designation.[2]

SGS has gained approval from Belgium's Federal Agency for Nuclear Control to resume human 14C ADME studies at its new Antwerp clinical pharmacology unit, enhancing early-phase CRO services for pharma sponsors.

South Korea's Ministry of Food and Drug Safety awards the first stress relief health claim to Affron Saffron, marking a regulatory milestone for pharmaceutical ingredients in the Asian market.

Prominent European biotech venture firms have formed the European Life Sciences Coalition to address the funding disparity faced by European drug startups compared to US and Chinese counterparts.

Pharmaceutical companies, including 16 with Trump pricing deals, raised list prices on 872 brand-name medications with a median 4% increase in early 2026, highlighting ongoing pricing trends amid policy efforts.[1]

EYE PCR has obtained CE Mark certification for its fixOflex endocapsular device under EU MDR, enabling commercialization across Europe for advanced cataract surgery applications.

HanchorBio announced that the U.S. FDA has granted Orphan Drug Designation to HCB101, a next-generation SIRPα-IgG4 Fc fusion protein, for treating gastric cancer, marking a key regulatory milestone.

Shanghai-based ArkBio gains FDA IND clearance to launch Phase 2 proof-of-concept trial for AK3280, a small-molecule anti-fibrotic therapy with promising China Phase 2 data.

The European Medicines Agency has published a new statement from the Drug Shortages Global Regulatory Working Group, addressing critical supply chain challenges in the pharmaceutical sector.